MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2023-05-16

No results posted yet for this study

Summary

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

Conditions

Interventions

DRUG

A197 Ophthalmic Solution

A197 Ophthalmic Solution

DRUG

A197 Vehicle Control

A197 Vehicle Control

DRUG

Active Comparator

Active Comparator

Sponsors & Collaborators

  • Aramis Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • David S Tierney, MD · Aramis Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-25
Primary Completion
2023-01-24
Completion
2023-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238597 on ClinicalTrials.gov